Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma
Go back to Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 9.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.65 | 52 Week High | $19.41 | |||
| Open | $9.65 | 52 Week Low | $4.83 | |||
| Day High | $9.65 | P/E | N/A | |||
| Day Low | $9.65 | EPS | $-2.74 | |||
| Volume | 1,639 | |||||
